Rimmyrah
Ranibizumab biosimilar developed by Qilu Pharmaceutical, development code QL1205. Reference product Lucentis.
About Rimmyrah
Rimmyrah is Qilu's ranibizumab, approved in Europe in January 2024 through Qilu's Spanish subsidiary. Qilu is one of the larger Chinese pharmaceutical companies and this was its first European biosimilar, with a pegfilgrastim now under review.
Status by market
United States
Not listed by FDA.
European Union · Rimmyrah
European Medicines Agency and European CommissionApprovedUnited Kingdom · Rimmyrah
Medicines and Healthcare products Regulatory AgencyApprovedJapan
Not listed by PMDA.
Canada
Not listed by HC.
India
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Rimmyrah holds an approval, these are the other ranibizumab biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| EMA | 5 | Bioeq (Cimerli / Ranivisio), Intas Pharmaceuticals (Rexatilux / Razumab), Lupin (Ranluspec / Vislyfa), Samsung Bioepis (Byooviz), Xbrane Biopharma (Ximluci) |
| MHRA | 4 | Lupin (Ranluspec / Vislyfa), Not stated in the MHRA list (Ongavia), Samsung Bioepis (Byooviz), Xbrane Biopharma (Ximluci) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Qilu Pharmaceutical: Nylaspeg.
Chronology
- EMAJan 2024Authorised by the European Commission as Rimmyrah
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)S023MHRA Products, substance lists of licensed medicines (products.mhra.gov.uk) Primary (regulator)
Planning ranibizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant